GZMK and non-small cell lung carcinoma: A recent single-cell transcriptomic study of NSCLC patients harboring rare driver mutations treated with anti-PD-1 therapy identified GZMK+ CD8 effector memory T cells as critical mediators of effective antitumor responses, whereas myeloid cells were implicated in promoting immunosuppressive mechanisms [20].